O-006Ultra-selection of metastatic colorectal cancer patients using next generation sequencing platform to improve clinical efficacy of anti-EGFR therapy

Introduction: Extended RAS and BRAF analysis is mandatory in metastatic colorectal cancer (mCRC) patients to establish the best therapeutic strategy. Recent studies aimed to determine the optimal threshold of RAS mutated subclones to identify patients most likely to benefit from anti-EGFR treatment (Laurent-Puig, CCR 2015; Santos C. Molec Can Ther 2017). Our aim is to assess the clinical relevance of highly sensitive Next Generation Sequencing (NGS) technology to detect point mutations in KRAS, NRAS, BRAF, and EGFR S492R in tissue tumor samples and its correlation with clinical outcome in terms of progression-free survival (PFS), overall response rate (ORR) and overall survival (OS) in mCRC patients treated with chemotherapy plus anti-EGFR or anti-VEGF therapy.